FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136095957> ?p ?o ?g. }

• W3136095957 endingPage "S163" @default.
• W3136095957 startingPage "S163" @default.
• W3136095957 abstract "ERBB2 mutations, mostly affecting the kinase domain (KD), were later found in the transmembrane domain (TMD), most frequently seen in residues V659, G660, but with a much lower prevalence. Comparing to other solid tumors, ERBB2-mutant NSCLC shows a lower response rate to HER2 inhibitors (HER2i). ERBB2 V659E has been reported to respond to lapatinib in combination with carpecitabine, afatinib, or ado-trastuzumab emtansine (TDM-1). However, since the prevalence of ERBB2 V659E is low, no study has reported the subsequent clinical management after developing resistance to HER2i. We retrospectively screened genomic profiles of 7,812 lung adenocarcinoma (LADC) patients. Molecular docking of lapatinib, afatinib and pyrotinib with the HER2 KD was simulated with AutoDock 4.2 and the binding affinity was predicted by MMPBSA.py program in AmberTools18. We analyzed NGS data of 7812 LADC patients and identified 14 patients (0.18%) with HER2 TMD mutation, mostly V659E mutation (11/7812, 0.14%); other mutations included V664F, T652M, V664F; each occurred in 1 patient. In this cohort, all adenocarcinomas harbor a dinucleotide missense mutation, including 10 TT→AA and 6 TT→AG (c.1976_1977). TP53 was the most frequently co-mutated gene (n=4) followed by HER2 amplification (n=2), NSD1 (n=2) and RARA (n=2). Treatment history of 9 advanced LADC patients was collected and analyzed. 3 of them had chemotherapy as first-line therapy. 5 patients were treated with HERi as first-line therapy, achieving a median PFS of 192 days (ranged from 60-515days), comparing to patients treated with chemotherapy (71.7±53.3days). 1 patient who was treated with different HERi sequentially in the order of lapatinib, afatinib, TDM-1, achieving an overall PFS of 515 days. Subsequently, she was treated with pyrotinib and had a PFS of 92 days. Molecular docking simulation showed the covalent inhibitors Afatinib and Pyrotinib are more favorable for blocking HER2 KD than non-covalent inhibitor Lapatinib. Between the two covalent inhibitors, Pyrotinib (ΔGPyrotinib = -65.92kcal/mol) shows stronger non-covalent binding ability than Afatinib (ΔGAfatinib = -59.71 kcal/mol) (p<0.001). To the best of our knowledge, this is the largest-reported HER2 V659E mutation cohort. We revealed the prevalence of ERBB2 V659E in Chinese LUAD patients and elucidated the genomic profile of ERBB2 V659E mutant. This study paves avenue for the utilization of the novel HER2 inhibitors pyrotinib in ERBB2 V659E mutant LUAD patients." @default.
• W3136095957 created "2021-03-29" @default.
• W3136095957 creator A5001127963 @default.
• W3136095957 creator A5008773780 @default.
• W3136095957 creator A5011560173 @default.
• W3136095957 creator A5020934667 @default.
• W3136095957 creator A5032988856 @default.
• W3136095957 creator A5035611017 @default.
• W3136095957 creator A5041448584 @default.
• W3136095957 creator A5041709423 @default.
• W3136095957 creator A5047447610 @default.
• W3136095957 creator A5048414136 @default.
• W3136095957 creator A5048661723 @default.
• W3136095957 creator A5056133341 @default.
• W3136095957 creator A5068599638 @default.
• W3136095957 creator A5070959241 @default.
• W3136095957 creator A5074799310 @default.
• W3136095957 creator A5075343454 @default.
• W3136095957 creator A5077549494 @default.
• W3136095957 creator A5079827830 @default.
• W3136095957 creator A5082203333 @default.
• W3136095957 creator A5090015472 @default.
• W3136095957 date "2021-03-01" @default.
• W3136095957 modified "2023-10-04" @default.
• W3136095957 title "MA08.09 Clinical Management of Lung Adenocarcinoma Patients With HER2 V659E Mutation" @default.
• W3136095957 doi "https://doi.org/10.1016/j.jtho.2021.01.195" @default.
• W3136095957 hasPublicationYear "2021" @default.
• W3136095957 type Work @default.
• W3136095957 sameAs 3136095957 @default.
• W3136095957 citedByCount "0" @default.
• W3136095957 crossrefType "journal-article" @default.
• W3136095957 hasAuthorship W3136095957A5001127963 @default.
• W3136095957 hasAuthorship W3136095957A5008773780 @default.
• W3136095957 hasAuthorship W3136095957A5011560173 @default.
• W3136095957 hasAuthorship W3136095957A5020934667 @default.
• W3136095957 hasAuthorship W3136095957A5032988856 @default.
• W3136095957 hasAuthorship W3136095957A5035611017 @default.
• W3136095957 hasAuthorship W3136095957A5041448584 @default.
• W3136095957 hasAuthorship W3136095957A5041709423 @default.
• W3136095957 hasAuthorship W3136095957A5047447610 @default.
• W3136095957 hasAuthorship W3136095957A5048414136 @default.
• W3136095957 hasAuthorship W3136095957A5048661723 @default.
• W3136095957 hasAuthorship W3136095957A5056133341 @default.
• W3136095957 hasAuthorship W3136095957A5068599638 @default.
• W3136095957 hasAuthorship W3136095957A5070959241 @default.
• W3136095957 hasAuthorship W3136095957A5074799310 @default.
• W3136095957 hasAuthorship W3136095957A5075343454 @default.
• W3136095957 hasAuthorship W3136095957A5077549494 @default.
• W3136095957 hasAuthorship W3136095957A5079827830 @default.
• W3136095957 hasAuthorship W3136095957A5082203333 @default.
• W3136095957 hasAuthorship W3136095957A5090015472 @default.
• W3136095957 hasBestOaLocation W31360959571 @default.
• W3136095957 hasConcept C104317684 @default.
• W3136095957 hasConcept C121608353 @default.
• W3136095957 hasConcept C126322002 @default.
• W3136095957 hasConcept C143998085 @default.
• W3136095957 hasConcept C2775999482 @default.
• W3136095957 hasConcept C2777329042 @default.
• W3136095957 hasConcept C2779438470 @default.
• W3136095957 hasConcept C2779786085 @default.
• W3136095957 hasConcept C2780580887 @default.
• W3136095957 hasConcept C2780586478 @default.
• W3136095957 hasConcept C2781182431 @default.
• W3136095957 hasConcept C501734568 @default.
• W3136095957 hasConcept C502942594 @default.
• W3136095957 hasConcept C530470458 @default.
• W3136095957 hasConcept C54355233 @default.
• W3136095957 hasConcept C71924100 @default.
• W3136095957 hasConcept C75563809 @default.
• W3136095957 hasConcept C86803240 @default.
• W3136095957 hasConcept C90924648 @default.
• W3136095957 hasConceptScore W3136095957C104317684 @default.
• W3136095957 hasConceptScore W3136095957C121608353 @default.
• W3136095957 hasConceptScore W3136095957C126322002 @default.
• W3136095957 hasConceptScore W3136095957C143998085 @default.
• W3136095957 hasConceptScore W3136095957C2775999482 @default.
• W3136095957 hasConceptScore W3136095957C2777329042 @default.
• W3136095957 hasConceptScore W3136095957C2779438470 @default.
• W3136095957 hasConceptScore W3136095957C2779786085 @default.
• W3136095957 hasConceptScore W3136095957C2780580887 @default.
• W3136095957 hasConceptScore W3136095957C2780586478 @default.
• W3136095957 hasConceptScore W3136095957C2781182431 @default.
• W3136095957 hasConceptScore W3136095957C501734568 @default.
• W3136095957 hasConceptScore W3136095957C502942594 @default.
• W3136095957 hasConceptScore W3136095957C530470458 @default.
• W3136095957 hasConceptScore W3136095957C54355233 @default.
• W3136095957 hasConceptScore W3136095957C71924100 @default.
• W3136095957 hasConceptScore W3136095957C75563809 @default.
• W3136095957 hasConceptScore W3136095957C86803240 @default.
• W3136095957 hasConceptScore W3136095957C90924648 @default.
• W3136095957 hasIssue "3" @default.
• W3136095957 hasLocation W31360959571 @default.
• W3136095957 hasOpenAccess W3136095957 @default.
• W3136095957 hasPrimaryLocation W31360959571 @default.
• W3136095957 hasRelatedWork W2005841680 @default.
• W3136095957 hasRelatedWork W2799307105 @default.
• W3136095957 hasRelatedWork W2884796310 @default.
• W3136095957 hasRelatedWork W2888534976 @default.

• next